HER2 Support Group Forums - View Single Post

Lani · 12-07-2006, 05:20 PM

I think MD Anderson looks at EGFR in its BRCA+ patients as they seem to often be triple negative and have an increased incidence of EGFR positivity...Also it gives them a possible targetted drug to treat with.

As neither Iressa, Tarceva and Erbitux is officially approved for breast cancer I think they feel testing would not be "clinically relevant" But if you don't test, you don't find out and you don't make progress against the disease.

My two cents.

12-07-2006, 05:20 PM	#21
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Alaska Angel I think MD Anderson looks at EGFR in its BRCA+ patients as they seem to often be triple negative and have an increased incidence of EGFR positivity...Also it gives them a possible targetted drug to treat with. As neither Iressa, Tarceva and Erbitux is officially approved for breast cancer I think they feel testing would not be "clinically relevant" But if you don't test, you don't find out and you don't make progress against the disease. My two cents.